Show simple item record

dc.contributor.authorMolenaar, Esther A.en_US
dc.contributor.authorHwang, Shih-Jenen_US
dc.contributor.authorVasan, Ramachandran S.en_US
dc.contributor.authorGrobbee, Diederick E.en_US
dc.contributor.authorMeigs, James B.en_US
dc.contributor.authorD'Agostino, Ralph B.en_US
dc.contributor.authorLevy, Danielen_US
dc.contributor.authorFox, Caroline S.en_US
dc.date.accessioned2011-12-29T21:03:22Z
dc.date.available2011-12-29T21:03:22Z
dc.date.issued2011-12-29
dc.identifier.citationMolenaar, Esther A., Shih-Jen Hwang, Ramachandran S. Vasan, Diederick E. Grobbee, James B. Meigs, Ralph B. D'Agostino, Daniel Levy, Caroline S. Fox. "Burden and Rates of Treatment and Control of Cardiovascular Disease Risk Factors in Obesity" Diabetes Care 31(7): 1367-1372. (2008)en_US
dc.identifier.issn1935-5548en_US
dc.identifier.urihttp://hdl.handle.net/2144/2546
dc.description.abstractOBJECTIVE: Obesity is associated with an increased risk for cardiovascular disease (CVD). We sought to determine rates of treatment and control of CVD risk factors among normal weight, overweight, and obese individuals in a community-based cohort. RESEARCH DESIGN AND METHODS: Participants free of CVD (n = 6,801; mean age 49 years; 54% women) from the Framingham Offspring and Third Generation cohorts who attended the seventh Offspring examination (1998–2001) or first Third Generation (2002–2005) examination were studied. RESULTS: Obese participants with hypertension were more likely to receive antihypertensive treatment (62.3%) than normal weight (58.7%) or overweight (59.0%) individuals (P = 0.002), but no differences in hypertension control across BMI subgroups among participants with hypertension were observed (36.7% [normal weight], 37.3% [overweight], and 39.4% [obese]; P = 0.48). Rates of lipid-lowering treatment were higher among obese participants with elevated LDL cholesterol (39.5%) compared with normal weight (34.2%) or overweight (36.4%) participants (P = 0.02), but control rates among those with elevated LDL cholesterol did not differ across BMI categories (26.7% [normal weight], 26.0% [overweight], and 29.2% [obese]; P = 0.11). There were no differences in diabetes treatment among participants with diabetes across BMI groups (69.2% [normal weight], 50.0% [overweight], 55.0% [obese]; P = 0.54), but obese participants with diabetes were less likely to have fasting blood glucose <126 mg/dl (15.7%) compared with normal weight (30.4%) or overweight (20.7%) participants (P = 0.02). CONCLUSIONS: These findings emphasize the suboptimal rates of treatment and control of CVD risk factors among overweight and obese individuals.en_US
dc.description.sponsorshipNational Insitutes of Health's National Heart, Lung, and Blood Association's Framingham Heart Study (N01-HC-25195); Netherlands Organization for Scientific Research; Netherlands Heart Foundation; National Heart, Lung, and Blood Institute (2K24 HL 04334); National Institute of Diabetes and Digestive and Kidney Diseases (K24 DK080140)en_US
dc.language.isoenen_US
dc.publisherAmerican Diabetes Associationen_US
dc.rightsCopyright 2008, American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.en_US
dc.titleBurden and Rates of Treatment and Control of Cardiovascular Disease Risk Factors in Obesityen_US
dc.typearticleen_US
dc.identifier.doi10.2337/dc07-2413en_US
dc.identifier.pubmedid18375414en_US
dc.identifier.pmcid2453683en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record